Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity

Noel M. Caplice, Cheryl S. Mueske, Laurel S. Kleppe, Robert D. Simari

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Background - Plaque disruption and exposure of subendothelial procoagulants such as tissue factor (TF) to circulating factor VII/VIIa (FVII/VIIa) lead to intravascular thrombosis. Tissue factor pathway inhibitor (TFPI) is an endogenous inhibitor of TF-induced coagulation that binds to factor Xa and the TF-FVIIa catalytic complex in a two-step process. The aim of this study was to determine the expression of TFPI within human atherosclerotic plaque and its role in modulation of TF activity. Methods and Results - We measured the level of TFPI antigen in human carotid plaque and determined the relationship between TFPI and TF activity within plaque. Furthermore, we examined the biological activity and immunolocalization patterns of TFPI within carotid plaque. TFPI was detectable (TFPI+ group) in 22 of 34 specimens (mean±SEM, 404.4±91.8 pg/mg) and undetectable (TFPI- group) in 12 of 34 specimens. In the TFPI- group, normalized TF activity was significantly greater than that in the TFPI+ group (0.28±0.04 vs 0.14±0.02 U/pg, P=0.002). Furthermore, neutralization of TFPI activity using a polyclonal antibody resulted in an 8-fold increase in TF activity in the TFPI+ group (P=0.001) but had no effect in the TFPI- group. Immunostaining for TFPI showed localization to endothelial cells, vascular smooth muscle cells within the fibrous cap region of the plaque, and macrophages within the shoulder region of the plaque. Conclusions - Taken together, these data suggest that biologically active TFPI is present within human atherosclerotic plaque and is associated with attenuated TF activity.

Original languageEnglish (US)
Pages (from-to)1051-1057
Number of pages7
JournalCirculation
Volume98
Issue number11
StatePublished - Sep 15 1998

Fingerprint

Thromboplastin
Atherosclerotic Plaques
lipoprotein-associated coagulation inhibitor
Factor VIIa
Factor VII
Factor Xa
Vascular Smooth Muscle
Smooth Muscle Myocytes

Keywords

  • Atherosclerosis
  • Inhibitor
  • Plaque
  • Tissue factor

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Caplice, N. M., Mueske, C. S., Kleppe, L. S., & Simari, R. D. (1998). Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation, 98(11), 1051-1057.

Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. / Caplice, Noel M.; Mueske, Cheryl S.; Kleppe, Laurel S.; Simari, Robert D.

In: Circulation, Vol. 98, No. 11, 15.09.1998, p. 1051-1057.

Research output: Contribution to journalArticle

Caplice, NM, Mueske, CS, Kleppe, LS & Simari, RD 1998, 'Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity', Circulation, vol. 98, no. 11, pp. 1051-1057.
Caplice, Noel M. ; Mueske, Cheryl S. ; Kleppe, Laurel S. ; Simari, Robert D. / Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. In: Circulation. 1998 ; Vol. 98, No. 11. pp. 1051-1057.
@article{7e5e384aff7a466d8191c4200dd4da14,
title = "Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity",
abstract = "Background - Plaque disruption and exposure of subendothelial procoagulants such as tissue factor (TF) to circulating factor VII/VIIa (FVII/VIIa) lead to intravascular thrombosis. Tissue factor pathway inhibitor (TFPI) is an endogenous inhibitor of TF-induced coagulation that binds to factor Xa and the TF-FVIIa catalytic complex in a two-step process. The aim of this study was to determine the expression of TFPI within human atherosclerotic plaque and its role in modulation of TF activity. Methods and Results - We measured the level of TFPI antigen in human carotid plaque and determined the relationship between TFPI and TF activity within plaque. Furthermore, we examined the biological activity and immunolocalization patterns of TFPI within carotid plaque. TFPI was detectable (TFPI+ group) in 22 of 34 specimens (mean±SEM, 404.4±91.8 pg/mg) and undetectable (TFPI- group) in 12 of 34 specimens. In the TFPI- group, normalized TF activity was significantly greater than that in the TFPI+ group (0.28±0.04 vs 0.14±0.02 U/pg, P=0.002). Furthermore, neutralization of TFPI activity using a polyclonal antibody resulted in an 8-fold increase in TF activity in the TFPI+ group (P=0.001) but had no effect in the TFPI- group. Immunostaining for TFPI showed localization to endothelial cells, vascular smooth muscle cells within the fibrous cap region of the plaque, and macrophages within the shoulder region of the plaque. Conclusions - Taken together, these data suggest that biologically active TFPI is present within human atherosclerotic plaque and is associated with attenuated TF activity.",
keywords = "Atherosclerosis, Inhibitor, Plaque, Tissue factor",
author = "Caplice, {Noel M.} and Mueske, {Cheryl S.} and Kleppe, {Laurel S.} and Simari, {Robert D.}",
year = "1998",
month = "9",
day = "15",
language = "English (US)",
volume = "98",
pages = "1051--1057",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity

AU - Caplice, Noel M.

AU - Mueske, Cheryl S.

AU - Kleppe, Laurel S.

AU - Simari, Robert D.

PY - 1998/9/15

Y1 - 1998/9/15

N2 - Background - Plaque disruption and exposure of subendothelial procoagulants such as tissue factor (TF) to circulating factor VII/VIIa (FVII/VIIa) lead to intravascular thrombosis. Tissue factor pathway inhibitor (TFPI) is an endogenous inhibitor of TF-induced coagulation that binds to factor Xa and the TF-FVIIa catalytic complex in a two-step process. The aim of this study was to determine the expression of TFPI within human atherosclerotic plaque and its role in modulation of TF activity. Methods and Results - We measured the level of TFPI antigen in human carotid plaque and determined the relationship between TFPI and TF activity within plaque. Furthermore, we examined the biological activity and immunolocalization patterns of TFPI within carotid plaque. TFPI was detectable (TFPI+ group) in 22 of 34 specimens (mean±SEM, 404.4±91.8 pg/mg) and undetectable (TFPI- group) in 12 of 34 specimens. In the TFPI- group, normalized TF activity was significantly greater than that in the TFPI+ group (0.28±0.04 vs 0.14±0.02 U/pg, P=0.002). Furthermore, neutralization of TFPI activity using a polyclonal antibody resulted in an 8-fold increase in TF activity in the TFPI+ group (P=0.001) but had no effect in the TFPI- group. Immunostaining for TFPI showed localization to endothelial cells, vascular smooth muscle cells within the fibrous cap region of the plaque, and macrophages within the shoulder region of the plaque. Conclusions - Taken together, these data suggest that biologically active TFPI is present within human atherosclerotic plaque and is associated with attenuated TF activity.

AB - Background - Plaque disruption and exposure of subendothelial procoagulants such as tissue factor (TF) to circulating factor VII/VIIa (FVII/VIIa) lead to intravascular thrombosis. Tissue factor pathway inhibitor (TFPI) is an endogenous inhibitor of TF-induced coagulation that binds to factor Xa and the TF-FVIIa catalytic complex in a two-step process. The aim of this study was to determine the expression of TFPI within human atherosclerotic plaque and its role in modulation of TF activity. Methods and Results - We measured the level of TFPI antigen in human carotid plaque and determined the relationship between TFPI and TF activity within plaque. Furthermore, we examined the biological activity and immunolocalization patterns of TFPI within carotid plaque. TFPI was detectable (TFPI+ group) in 22 of 34 specimens (mean±SEM, 404.4±91.8 pg/mg) and undetectable (TFPI- group) in 12 of 34 specimens. In the TFPI- group, normalized TF activity was significantly greater than that in the TFPI+ group (0.28±0.04 vs 0.14±0.02 U/pg, P=0.002). Furthermore, neutralization of TFPI activity using a polyclonal antibody resulted in an 8-fold increase in TF activity in the TFPI+ group (P=0.001) but had no effect in the TFPI- group. Immunostaining for TFPI showed localization to endothelial cells, vascular smooth muscle cells within the fibrous cap region of the plaque, and macrophages within the shoulder region of the plaque. Conclusions - Taken together, these data suggest that biologically active TFPI is present within human atherosclerotic plaque and is associated with attenuated TF activity.

KW - Atherosclerosis

KW - Inhibitor

KW - Plaque

KW - Tissue factor

UR - http://www.scopus.com/inward/record.url?scp=0032530146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032530146&partnerID=8YFLogxK

M3 - Article

C2 - 9736590

AN - SCOPUS:0032530146

VL - 98

SP - 1051

EP - 1057

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 11

ER -